Ticlopidine contraindications: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) |
Ahmed Zaghw (talk | contribs) |
||
| Line 9: | Line 9: | ||
:*'''[[Hypersensitivity]]''' to the drug. | :*'''[[Hypersensitivity]]''' to the drug. | ||
:*Presence of '''hematopoietic disorders''' such as [[neutropenia]] and [[thrombocytopenia]] or a past history of either [[TTP]] or [[aplastic anemia]]. | :*Presence of '''hematopoietic disorders''' such as [[neutropenia]] and [[thrombocytopenia]] or a past history of either [[TTP]] or [[aplastic anemia]]. | ||
:*Presence of a '''hemostatic disorder''' or active pathological bleeding (such as bleeding [[peptic ulcer]] or [[intracranial bleeding]]). | :*Presence of a '''hemostatic disorder''' or active pathological bleeding (such as bleeding '''[[peptic ulcer]]''' or '''[[intracranial bleeding]]'''). | ||
:*Patients with '''severe [[Hepatic failure|liver impairment]]'''. | :*Patients with '''severe [[Hepatic failure|liver impairment]]'''. | ||
Revision as of 00:45, 6 February 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Contraindications
The use of ticlopidine hydrochloride is contraindicated in the following conditions[1]:
- Hypersensitivity to the drug.
- Presence of hematopoietic disorders such as neutropenia and thrombocytopenia or a past history of either TTP or aplastic anemia.
- Presence of a hemostatic disorder or active pathological bleeding (such as bleeding peptic ulcer or intracranial bleeding).
- Patients with severe liver impairment.
References
Adapted from the FDA Package Insert.